Nadir Abbas, Emma L Culver, Douglas Thorburn, Neil Halliday, Hannah Crothers, Jessica K Dyson, April Phaw, Richard Aspinall, Salim I Khakoo, Yiannis Kallis, Belinda Smith, Imran Patanwala, Anne McCune, Chenchu R Chimakurthi, Vinod Hegade, Michael Orrell, Rebecca Jones, George Mells, Colette Thain, Robert-Mitchell Thain, David Jones, Gideon Hirschfield, Palak J Trivedi
BACKGROUND AND AIMS: One-third of patients with primary biliary cholangitis (PBC) inadequately respond to ursodeoxycholic acid (UDCA). Our aim was to assemble national, real-world data on the effectiveness of obeticholic acid (OCA) as a second-line treatment, alongside non-licensed therapy with fibric acid derivatives (bezafibrate/fenofibrate). METHODS: This was a nationwide observational cohort study conducted from August 2017 until June 2021. RESULTS: We accrued data from 457 patients; 349 treated with OCA and 108 with fibric acid derivatives...
August 8, 2022: Clinical Gastroenterology and Hepatology